DAA therapy induces a high LDR rate in HCV-associated indolent lymphomas. These data provide a strong rationale for prospective trials with DAAs in this setting.
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Key points:
Direct-acting antivirals agents are able to induce lymphoma response in patients with HCV-associated indolent non-Hodgkin lymphoma.
The highest rate of lymphoma response (73%) was observed in patients with marginal zone lymphoma.
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ABSTRACT
Regression of hepatitis C virus (HCV)-associated lymphoma with interferon-based antiviral treatment supports an etiological link between lymphoma and HCV infection. In addition, a favorable impact of antiviral treatment on overall survival of patients with HCV-related lymphoma has been reported. Data on IFN-free regimens combining direct-acting antivirals (DAAs) in HCV-associated lymphoproliferative disorders are scanty.
We analyzed virological and lymphoproliferative disease response (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL) and chronic HCV infection treated with DAAs.
Histological distribution was: 37 marginal zone lymphomas (MZL), 2 lymphoplasmacytic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphoma (SLL), 1 lowgrade NHL not otherwise specified. Thirty-nine patients received a Sofosbuvir-based regimen and 7 patients other DAAs. Median duration of DAA therapy was 12 weeks (range 6-24 weeks). A sustained virological response at week 12 after finishing DAAs was obtained in 45 patients (98%); overall LDR rate was 67% including 12 patients (26%) achieving a complete response. LDR rate was 73% among patients with MZL while no response was observed in CLL/SLL patients. Seven patients cleared cryoglobulins out of 15 initially positive. After a median follow up of 8 months, 1-year progression-free and overall survival were 75% [95% confidence interval: 51% -88%] and 98% [86-100%], respectively. DAA therapy induces a high LDR rate in HCV-associated indolent lymphomas. These data provide a strong rationale for prospective trials with DAAs in this setting.
INTRODUCTION
In addition to liver disease, hepatitis C virus (HCV) infection has been linked to the development of type II mixed cryoglobulinemia and to a spectrum of B-cell lymphoproliferative disorders.
1 Systematic reviews of epidemiological studies evaluating the prevalence of HCV infection in B-cell non-Hodgkin lymphomas (B-NHL) confirmed that HCV prevalence is higher in patients with B-NHL than in general population, supporting a role of HCV in the etiology of B-NHL. 2 In subtype-specific analysis, HCV infection is associated with marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL) and lymphoplasmacytic lymphoma (LPL). 3 The pathophysiology of HCV-associated B-NHL, at least for MZL, appears to be linked to chronic antigenic stimulation, as several reports
show that the clearance of HCV infection with interferon (IFN)-based antiviral therapy often results in regression of the tumor burden. 4, 5 The favorable impact of IFN-based antiviral therapy on the outcome of these patients has been consistently reported in the Fondazione Italiana Linfomi study 5 and in the French ANRS HC-13 Lympho-C study. 6 However, a direct anti-proliferative effect of IFN on malignant lymphocytes cannot be ruled out. 
METHODS
Study design and patients
We retrospectively selected patients affected by indolent B-NHL or chronic lymphocytic leukemia (CLL) and infected by HCV defined as HCV-RNA positivity and treated with DAAs within Italian centers of Fondazione Italiana Linfomi, the French ANRS-CO22 HEPATHER cohort, in a German center (Frankfurt) and in a United States center (Houston).
Five patients were already reported in the literature [10] [11] [12] and were included with updated follow-up. Approval for this study, which was based on the use of archival or cohort data, was obtained from the Institutional Review Boards of participating centers. The report was prepared in accordance with the STROBE statement. 13 Data management and analysis were carried out in accordance with the tenets of the Declaration of Helsinki of 1964, as revised in 2000. All patients gave informed consent.
Clinical and virological end-points
The primary end-point was overall response rate (ORR); complete response (CR), partial response (PR) rates, progression-free survival (PFS) and overall survival (OS) were secondary end-points. PFS was defined as the time interval between the start of DAA therapy and lymphoma progression, initiation of new treatment, or death. Response evaluation was based on Lugano classification criteria for lymphomas 14 and on guidelines from the International Workshop on CLL. 15 Specific examinations were carried out for response assessment in specific lymphoma subtypes, according to clinical presentation (i.e. paraprotein level when present before DAA). Bone marrow biopsy was repeated at the end of DAA only in cases that were positive at study entry. Response assessment was performed one month after the end of DAA therapy. Sustained virological response (SVR) was defined as undetectable HCV viral load (<15 IU/ml) 12 weeks after completion of therapy.
Statistical analysis
The Fisher's exact test was used to explore associations between categorical variables. The
Wilcoxon rank-sum test was applied to test differences of quantitative variables between two independent groups. The associations between clinical variables and non-response were reported in terms of Odds Ratio (OR), 95% confidence interval (95% CI) and significance level (p-value). All variables with a p-value ≤ 0.1 in the univariate analysis of non-response were included in a multivariate logistic model. The Kaplan-Meier product-limit method was used to estimate PFS and OS. All computations were carried out using Stata 12.1 (2007).
RESULTS
Hematological and virological features
Hematological and virological characteristics of the 46 study patients are summarized in weekly Rituximab doses were added to DAA. All patients, except one who received only 6 weeks of DAA therapy for early progression, were treated with the whole course of DAA therapy.
Toxicity
Toxicity of treatment was negligible: 13 patients had grade 1-2 adverse events (including five cases of anemia in patients treated with ribavirin) and only one grade 3 event was registered (asthenia).
Virological response and lymphoproliferative disease response
DAA treatment led to a virological response in all patients except one who had decompensated cirrhosis. Hematological ORR was 67%, CR being obtained in 12 cases 
DISCUSSION
Here, we report the first large series of patients with HCV-associated lymphoproliferative disorders treated with IFN-free DAA therapy. As described in HCV infection without lymphoma 16 , this study confirms that virological response is obtained in nearly all patients with chronic HCV infection (98%). This high rate of virological response was associated to an overall LDR rate of 67% including complete and partial responses in 26% and in 41% of patients, respectively.
Epidemiological studies provide strong evidences for an association of HCV infection with B-cell lymphoproliferative disorders, in particular with the histological subtypes MZL 17 and DLBCL. 18, 19 The most convincing evidence for a causal relationship between HCV infection and lymphoma development is the observation of lymphoma regression after HCV eradication by antiviral therapy. [4] [5] [6] 20 In a recent meta-analysis of 20 studies (254 patients)
evaluating the efficacy of IFN-based treatment in HCV-related NHL, overall lymphoma response rate after IFN-based antiviral therapy was 73% which is similar to the ORR reported in the present study. 21 In studies using IFN-based antivirals in which rate of virological response was lower, a strong correlation between virus clearance and lymphoma response has been established. In the present study, the only patient who did not achieve SVR at week 12
to DAA also underwent lymphoma progression leading to early death.
Regarding the association between histological type and lymphoma response, in the above cited metanalysis 21 , there was a trend towards favorable response for antivirals in HCVassociated MZL (response rate 81%), compared to non-marginal zone lymphomas (response rate 71%). The higher lymphoma response rate in MZL is confirmed in our series: ORR is 73% for MZL and 44% for non-MZL. Of note, MZL subtype exhibits similar response rates than those obtained with IFN-based regimen. Taking into account the relatively low number of cases, we found trends for a better lymphoma response in patients with extranodal disease and paraproteinemia, features typically associated with HCV-associated NHLs. [22] [23] [24] Finally, in CLL/SLL, that are not constantly epidemiologically associated with HCV infection 3, 25 , no LDR were achieved despite virus clearance. Altogether, these findings confirm that HCV clearance per se is beneficial in patients with non CLL/SLL HCV-associated B-NHL and support a stepwise model of lymphomagenesis induced by chronic antigenic stimulation in this setting.
Taken together, considering the favorable impact of IFN-based antivirals on outcome of HCV-infected NHL patients, 5, 6 our data strongly suggest that antiviral treatment should be used as the first option for HCV-associated MZL when cytoreductive treatment is not immediately necessary. [26] [27] [28] An extended follow up of this series will be necessary to confirm Marginal zone lymphomas (n=37) 11 16 6 Splenic (n=17) NHL: non-Hodgkin lymphoma; NOS: not otherwise specified; CLL: chronic lymphocytic leukemia; SLL: small lymphocytic lymphoma *: follicular lymphoma (n=2); lymphoplasmacytic lymphoma (n=2); low-grade B-cell nonHodgkin lymphoma not otherwise specified (n=1).
